NINTEDANIB PLUS LETROZOLE IN EARLY BREAST CANCER: A PHASE 0/I PHARMACODYNAMIC, PHARMACOKINETIC, AND SAFETY CLINICAL TRIAL OF COMBINED FGFR1 AND AROMATASE INHIBITION

Abstract Background The combined use of a FGFR1 blocker and Locomotive aromatase inhibitors is appealing for treating breast cancer patients with FGFR1 amplification.However, no pharmacodynamic studies have addressed the effects of this combined target modulation.We conducted a phase 0/I clinical trial in an adjuvant setting, with the goal of obtai

Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease characterized by repetitive alveolar injuries with excessive deposition of extracellular matrix (ECM) proteins.A crucial need in understanding IPF pathogenesis is identifying cell types associated with histopathological regions, particularly local fibrosis centers known as fibroblast

An MECS (multiple energy copyright system) could meet diverse energy needs owing to the integration of different energy carriers, while the distinction of quality of different energy resources should be taken into account during the operation stage, in addition the economic principle.Hence, in this paper, the concept of exergy is adopted to evaluat